Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7Multiple Myeloma 7Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Sezary Syndrome 2Recurrence 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoproliferative Disorders 2Immune System Diseases 2Vascular Diseases 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Paraproteinemias 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × Vorinostat × Clear all
NCT00907738 2015-05-21

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Merck Sharp & Dohme LLC

Phase 2 Completed
27 enrolled 9 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡